|
1
|
Keith RL and Miller YE: Lung cancer
chemoprevention: current status and future prospects. Nat Rev Clin
Oncol. 10:334–343. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
She J, Yang P, Hong Q and Bai C: Lung
cancer in China: challenges and interventions. Chest.
143:1117–1126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yang Y, Li H, Hou S, Hu B, Liu J and Wang
J: The noncoding RNA expression profile and the effect of lncRNA
AK126698 on cisplatin resistance in non-small-cell lung cancer
cell. PLoS One. 8:e653092013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grutters JPC, Kessels AGH,
Pijls-Johannesma M, de Ruysscher D, Joore MA and Lambin P:
Comparison of the effectiveness of radiotherapy with photons,
protons and carbon-ions for non-small cell lung cancer: a
meta-analysis. Radiother Oncol. 95:32–40. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Herbst R, Heymach J and Lippman S:
Molecular origins of cancer. N Engl J Med. 359:1367–1380. 2008.
|
|
6
|
Schiller JH, Harrington D, Belani CP, et
al: Comparison of four chemotherapy regimens for advanced
non-small-cell lung cancer. N Engl J Med. 346:92–98. 2002.
View Article : Google Scholar
|
|
7
|
Scagliotti GV, Parikh P, von Pawel J, et
al: Phase III study comparing cisplatin plus gemcitabine with
cisplatin plus pemetrexed in chemotherapy-naive patients with
advanced-stage non-small-cell lung cancer. J Clin Oncol.
26:3543–3551. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mackay HJ and Twelves CJ: Protein kinase
C: a target for anticancer drugs? Endocr Relat Cancer. 10:389–396.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hiss D: Optimizing molecular-targeted
therapies in ovarian cancer: the renewed surge of interest in
ovarian cancer biomarkers and cell signaling pathways. J Oncol.
2012:7379812012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jenkins DC, Charles IG, Thomsen LL, et al:
Roles of nitric oxide in tumor growth. Proc Natl Acad Sci USA.
92:4392–4396. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu WM, Liu LZ, Loizidou M, Ahmed M and
Charles IG: The role of nitric oxide in cancer. Cell Res.
12:311–320. 2002. View Article : Google Scholar
|
|
12
|
Chen GG, Lee TW, Xu H, Yip JH, Li M, Mok
TS and Yim AP: Increased inducible nitric oxide synthase in lung
carcinoma of smokers. Cancer. 112:372–381. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wongvaranon P, Pongrakhananon V, Chunhacha
P and Chanvorachote P: Acquired resistance to chemotherapy in lung
cancer cells mediated by prolonged nitric oxide exposure.
Anticancer Res. 33:5433–5444. 2013.PubMed/NCBI
|
|
14
|
Du Q, Zhang X, Liu Q, Zhang X, Bartels CE
and Geller DA: Nitric oxide production upregulates Wnt/β-catenin
signaling by inhibiting Dickkopf-1. Cancer Res. 73:6526–6537.
2013.PubMed/NCBI
|
|
15
|
Vane JR, Mitchell JA, Appleton I, et al:
Inducible isoforms of cyclooxygenase and nitric-oxide synthase in
inflammation. Proc Natl Acad Sci USA. 91:2046–2050. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nathan C and Xie QW: Nitric oxide
synthases: roles, tolls, and controls. Cell. 78:915–918. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gonzalez D, Rojas A, Herrera MB and Conlan
RS: iNOS activation regulates β-catenin association with its
partners in endothelial cells. PLoS One. 7:e529642012.
|
|
18
|
Sumi T, Oki S, Kitajima K and Meno C:
Epiblast ground state is controlled by canonical Wnt/β-catenin
signaling in the post-implantation mouse embryo and epiblast stem
cells. PLoS One. 8:e633782013.PubMed/NCBI
|
|
19
|
Tian XH, Hou WJ, Fang Y, et al: XAV939, a
tankyrase 1 inhibitor, promotes cell apoptosis in neuroblastoma
cell lines by inhibitingWnt/β-catenin signaling pathway. J Exp Clin
Cancer Res. 32:1002013.
|
|
20
|
Gafni J, Munsch JA, Lam TH, et al:
Xestospongins: potent membrane permeable blockers of the inositol
1,4,5-trisphosphate receptor. Neuron. 19:723–733. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Westfall TA, Brimeyer R, Twedt J, et al:
Wnt-5/pipetail functions in vertebrate axis formation as a negative
regulator of Wnt/beta-catenin activity. J Cell Biol. 162:889–898.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cadigan KM and Nusse R: Wnt signaling: a
common theme in animal development. Genes Dev. 11:3286–3305. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Logan CY and Nusse R: The Wnt signaling
pathway in development and disease. Annu Rev Cell Dev Biol.
20:781–810. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moon RT, Brown JD and Torres M: WNTs
modulate cell fate and behavior during vertebrate development.
Trends Genet. 13:157–162. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nakajima M, Fukuchi M, Miyazaki T, Masuda
N, Kato H and Kuwano H: Reduced expression of Axin correlates with
tumour progression of oesophageal squamous cell carcinoma. Br J
Cancer. 88:1734–1739. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bryja V, Andersson ER, Schambony A, et al:
The extracellular domain of Lrp5/6 inhibits noncanonical Wnt
signaling in vivo. Mol Biol Cell. 20:924–936. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Andersson ER, Bryjova L, Biris K,
Yamaguchi TP, Arenas E and Bryja V: Genetic interaction between
Lrp6 and Wnt5a during mouse development. Dev Dyn. 239:237–245.
2010.PubMed/NCBI
|
|
28
|
Gao C and Chen YG: Dishevelled: The hub of
Wnt signaling. Cell Signal. 22:717–727. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mikels AJ and Nusse R: Purified Wnt5a
protein activates or inhibits beta-catenin-TCF signaling depending
on receptor context. PLoS Biol. 4:570–582. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Surana R, Sikka S, Cai W, Dharmarajan AM,
Kumar AP, et al: Secreted frizzled related proteins: implications
in cancers. Biochim Biophys Acta. 1845:53–65. 2014.PubMed/NCBI
|
|
31
|
Zhang J, Zhou B, Liu Y, et al: Wnt
inhibitory factor-1 functions as a tumor suppressor through
modulating Wnt/β-catenin signaling in neuroblastoma. Cancer Lett.
348:12–19. 2014.PubMed/NCBI
|
|
32
|
Kawano Y and Kypta R: Secreted antagonists
of the Wnt signalling pathway. J Cell Sci. 116:2627–2634. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Bafico A, Liu G, Yaniv A, Gazit A and
Aaronson SA: Novel mechanism of Wnt signalling inhibition mediated
by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol.
3:683–686. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Du Q, Park KS, Guo Z, et al: Regulation of
human nitric oxide synthase 2 expression by Wnt beta-catenin
signaling. Cancer Res. 66:7024–7031. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Du Q, Zhang X, Cardinal J, et al:
Wnt/beta-catenin signaling regulates cytokine-induced human
inducible nitric oxide synthase expression by inhibiting nuclear
factor-kappaB activation in cancer cells. Cancer Res. 69:3764–3771.
2009. View Article : Google Scholar
|
|
36
|
Du Q and Geller DA: Cross-regulation
between Wnt and NF-κB signaling pathways. For Immunopathol Dis
Therap. 1:155–181. 2010.
|
|
37
|
Pakos EE and Ioannidis JP: The association
of P-glycoprotein with response to chemotherapy and clinical
outcome in patients with osteosarcoma. A meta-analysis. Cancer.
8:581–589. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Geng G, Wang L, Chen X, Cao R and Li P:
The association between chemosensitivity and Pgp, GST-π and Topo II
expression in gastric cancer. Diagn Pathol. 8:1982013.PubMed/NCBI
|
|
39
|
MacDonald BT and He X: Frizzled and LRP5/6
receptors for Wnt/β-catenin signaling. Cold Spring Harb Perspect
Biol. 4:a0078802012.
|
|
40
|
Bourhis E, Tam C, Franke Y, et al:
Reconstitution of a Frizzled8-Wnt3a-LRP6 signaling complex reveals
multiple Wnt and Dkk1 binding sites on LRP6. J Biol Chem.
285:9172–9179. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tamai K, Semenov M, Kato Y, et al:
LDL-receptor-related proteins in Wnt signal transduction. Nature.
407:530–535. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hsieh JC, Kodjabachian L, Rebbert ML, et
al: A new secreted protein that binds to Wnt proteins and inhibits
their activities. Nature. 398:431–436. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Surmann-Schmitt C, Widmann N, Dietz U, et
al: Wif-1 is expressed at cartilage-mesenchyme interfaces and
impedes Wnt3a-mediated inhibition of chondrogenesis. J Cell Sci.
122:3627–3637. 2009. View Article : Google Scholar : PubMed/NCBI
|
